Giuseppe Saglio
Giuseppe Saglio
Professore di Ematologia, Universita' di Torino
Email verificata su
Citata da
Citata da
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, ...
New England Journal of Medicine 348 (11), 994-1004, 2003
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ...
New England Journal of Medicine 355 (23), 2408-2417, 2006
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
H Kantarjian, C Sawyers, A Hochhaus, F Guilhot, C Schiffer, ...
New England Journal of Medicine 346 (9), 645-652, 2002
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ...
Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
B Falini, C Mecucci, E Tiacci, M Alcalay, R Rosati, L Pasqualucci, ...
New England Journal of Medicine 352 (3), 254-266, 2005
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil, P Le Coutre, G Etienne, C Lobo, ...
New England Journal of Medicine 362 (24), 2251-2259, 2010
Standardization and quality control studies of ‘real-time’quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection …
J Gabert, E Beillard, VHJ Van der Velden, W Bi, D Grimwade, ...
Leukemia 17 (12), 2318-2357, 2003
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ...
Journal of clinical oncology 27 (35), 6041-6051, 2009
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
M Baccarani, G Saglio, J Goldman, A Hochhaus, B Simonsson, ...
Blood 108 (6), 1809-1820, 2006
Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
JJM Van Dongen, EA Macintyre, JA Gabert, E Delabesse, V Rossi, ...
Leukemia 13 (12), 1901-1928, 1999
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL …
T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ...
Blood 108 (1), 28-37, 2006
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ...
Leukemia 34 (4), 966-984, 2020
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’quantitative reverse-transcriptase polymerase chain …
E Beillard, N Pallisgaard, VHJ Van der Velden, W Bi, R Dee, ...
Leukemia 17 (12), 2474-2486, 2003
Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial
JE Cortes, G Saglio, HM Kantarjian, M Baccarani, J Mayer, C Boqué, ...
Journal of Clinical Oncology 34 (20), 2333-2340, 2016
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson, DW Kim, S Issaragrisil, ...
Leukemia 30 (5), 1044-1054, 2016
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European …
S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ...
Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011
PML targeting eradicates quiescent leukaemia-initiating cells
K Ito, R Bernardi, A Morotti, S Matsuoka, G Saglio, Y Ikeda, J Rosenblatt, ...
Nature 453 (7198), 1072-1078, 2008
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Experts in Chronic Myeloid Leukemia
Blood, The Journal of the American Society of Hematology 121 (22), 4439-4442, 2013
Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy
F Mandelli, D Diverio, G Avvisati, A Luciano, T Barbui, C Bernasconi, ...
Blood, The Journal of the American Society of Hematology 90 (3), 1014-1021, 1997
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ...
Clinical Cancer Research 12 (24), 7374-7379, 2006
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20